Can-Fite BioPharma (CANF) shares were up over 90% in recent Wednesday trading after the company said its phase 2a study of namodenoson in patients with advanced pancreatic ductal adenocarcinoma met its primary endpoint.

The study, which enrolled 20 patients who had received one or more prior lines of therapy, showed that namodenoson was very well tolerated, and no new safety signals were identified, it said.

Survival follow-up remains ongoing, with 1/3 of patients currently alive at the time of data cut-off, the company said.

Price: 9.62, Change: +4.62, Percent Change: +92.40